U.S. Markets open in 14 mins
  • S&P Futures

    3,924.50
    +8.25 (+0.21%)
     
  • Dow Futures

    31,521.00
    +34.00 (+0.11%)
     
  • Nasdaq Futures

    12,170.25
    +29.75 (+0.25%)
     
  • Russell 2000 Futures

    1,765.50
    +3.80 (+0.22%)
     
  • Crude Oil

    108.18
    +0.56 (+0.52%)
     
  • Gold

    1,835.50
    +5.20 (+0.28%)
     
  • Silver

    21.41
    +0.28 (+1.35%)
     
  • EUR/USD

    1.0586
    +0.0028 (+0.2647%)
     
  • 10-Yr Bond

    3.1900
    +0.0650 (+2.08%)
     
  • Vix

    28.20
    -0.85 (-2.93%)
     
  • GBP/USD

    1.2273
    +0.0003 (+0.0245%)
     
  • USD/JPY

    135.2500
    +0.0800 (+0.0592%)
     
  • BTC-USD

    21,252.72
    -145.90 (-0.68%)
     
  • CMC Crypto 200

    463.31
    +9.41 (+2.07%)
     
  • FTSE 100

    7,243.10
    +34.29 (+0.48%)
     
  • Nikkei 225

    26,871.27
    +379.30 (+1.43%)
     

Innoviva Acquires AstraZeneca-Spin Off At $2.20/Share

  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
·1 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
  • Innoviva Inc (NASDAQ: INVA) has agreed to acquire Entasis Therapeutics Holdings Inc (NASDAQ: ETTX) at $2.20 per share in cash.

  • Innoviva currently owns approximately 60% of the outstanding shares of Entasis common stock. The acquisition consideration values Entasis' equity at $113 million on a fully diluted basis.

  • "This acquisition will build upon our overall strategy to acquire differentiated, high-potential assets in attractive, yet often overlooked, disease areas where our capital and capabilities can make a difference," said Pavel Raifeld, Chief Executive Officer of Innoviva.

  • "We look forward to working with the Entasis team to advance sulbactam-durlobactam (SUL-DUR) and its broader novel antibacterial pipeline to address the urgent and serious threat posed by multidrug-resistant pathogens," Raifeld added.

  • Established in 2015 as a spin-out from AstraZeneca Plc (NASDAQ: AZN), Entasis' pathogen-targeted approach has produced a robust clinical and pre-clinical pipeline of potential medicines for multidrug-resistant Gram-negative bacteria, including lead asset SUL-DUR.

  • In the Phase 3 trial, SUL-DUR achieved all primary and secondary endpoints. An FDA marketing application is expected to be submitted in Q3 of 2022.

  • Price Action: ETTX shares are up 21.1% at $2.18 during the market session on the last check Monday.

See more from Benzinga

Don't miss real-time alerts on your stocks - join Benzinga Pro for free! Try the tool that will help you invest smarter, faster, and better.

© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.